curcumin and carfilzomib

curcumin has been researched along with carfilzomib* in 2 studies

Other Studies

2 other study(ies) available for curcumin and carfilzomib

Article	Year
Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways. Toxicology in vitro : an international journal published in association with BIBRA, 2018, Volume: 47 Multiple myeloma (MM) is a malignant B-cell neoplasm with accumulation of malignant plasma cells in bone marrow. Pharmacological therapy improves response frequency even if with various associated toxicities. Herein, we investigated if combination of curcumin with carfilzomib (CFZ) can induce a better cytotoxic effect on in vitro cultured U266 cells. Cell viability data showed that curcumin significantly ameliorates CFZ cytotoxic effect. Furthermore, curcumin alone did not affect proteasome at the tested dose, confirming the involvement of different mechanisms in the observed effects. U266 cells exposure to curcumin or CFZ increased reactive species (RS) levels, although their production did not appear further potentiated following drugs combination. Interestingly, NF-κB nuclear accumulation was reduced by treatment with CFZ or curcumin, and was more deeply decreased in cells treated with CFZ-curcumin combinations, very likely due to the different mechanisms through which they target NF-κB. Our results confirmed the induction of p53/p21 axis and G0/G1 cell cycle arrest in anticancer activities of both drugs, an effect more pronounced for the CFZ-curcumin tested combinations. Furthermore, curcumin addition enhanced CFZ proapoptotic effect. These findings evidence that curcumin can ameliorate CFZ efficacy, and lead us to hypothesize that this effect might be useful to optimize CFZ therapy in MM patients. Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Curcumin; Humans; Multiple Myeloma; Neoplasm Proteins; NF-kappa B p50 Subunit; Oligopeptides; Osmolar Concentration; Oxidative Stress; Proteasome Inhibitors; Reactive Oxygen Species; Resting Phase, Cell Cycle; Signal Transduction; Tumor Suppressor Protein p53	2018
Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2. Proceedings of the National Academy of Sciences of the United States of America, 2018, 08-07, Volume: 115, Issue:32 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; CRISPR-Cas Systems; Crystallography, X-Ray; Curcumin; Drug Synergism; Dyrk Kinases; Female; Gene Editing; Gene Knockout Techniques; HEK293 Cells; Humans; Inhibitory Concentration 50; Mice; Neoplasms; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays	2018

Article

Year

Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways.

Toxicology in vitro : an international journal published in association with BIBRA, 2018, Volume: 47

Multiple myeloma (MM) is a malignant B-cell neoplasm with accumulation of malignant plasma cells in bone marrow. Pharmacological therapy improves response frequency even if with various associated toxicities. Herein, we investigated if combination of curcumin with carfilzomib (CFZ) can induce a better cytotoxic effect on in vitro cultured U266 cells. Cell viability data showed that curcumin significantly ameliorates CFZ cytotoxic effect. Furthermore, curcumin alone did not affect proteasome at the tested dose, confirming the involvement of different mechanisms in the observed effects. U266 cells exposure to curcumin or CFZ increased reactive species (RS) levels, although their production did not appear further potentiated following drugs combination. Interestingly, NF-κB nuclear accumulation was reduced by treatment with CFZ or curcumin, and was more deeply decreased in cells treated with CFZ-curcumin combinations, very likely due to the different mechanisms through which they target NF-κB. Our results confirmed the induction of p53/p21 axis and G0/G1 cell cycle arrest in anticancer activities of both drugs, an effect more pronounced for the CFZ-curcumin tested combinations. Furthermore, curcumin addition enhanced CFZ proapoptotic effect. These findings evidence that curcumin can ameliorate CFZ efficacy, and lead us to hypothesize that this effect might be useful to optimize CFZ therapy in MM patients.

Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Curcumin; Humans; Multiple Myeloma; Neoplasm Proteins; NF-kappa B p50 Subunit; Oligopeptides; Osmolar Concentration; Oxidative Stress; Proteasome Inhibitors; Reactive Oxygen Species; Resting Phase, Cell Cycle; Signal Transduction; Tumor Suppressor Protein p53

2018

Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2.

Proceedings of the National Academy of Sciences of the United States of America, 2018, 08-07, Volume: 115, Issue:32

Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; CRISPR-Cas Systems; Crystallography, X-Ray; Curcumin; Drug Synergism; Dyrk Kinases; Female; Gene Editing; Gene Knockout Techniques; HEK293 Cells; Humans; Inhibitory Concentration 50; Mice; Neoplasms; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays

2018